High prevalence of anxiety and depression in patients with primary open-angle glaucoma

J Glaucoma. Oct-Nov 2008;17(7):552-7. doi: 10.1097/IJG.0b013e31816299d4.

Abstract

Purpose: To assess anxiety and depression in patients with primary open-angle glaucoma (POAG).

Design: Multicenter prospective case-control study.

Participants: Two hundred thirty patients with POAG and 230 sex-matched and age-matched reference subjects with no chronic ocular conditions except cataracts.

Intervention: Anxiety and depression were evaluated using Hospital Anxiety and Depression Scale (HADS) questionnaire, which consists of 2 subscales with ranges of 0 to 21, representing anxiety (HADS-A) and depression (HADS-D).

Main outcome measure: The prevalence of POAG patients with anxiety (a score of more than 10 on the HADS-A) or depression (a score of more than 10 on the HADS-D) was compared with that in the reference subjects. The prevalence of patients with depression was compared between the POAG patients with and without current beta-blocker eye drops.

Results: The prevalence (13.0%) of POAG patients with anxiety was significantly higher (P=0.030) than in the reference subjects (7.0%). The prevalence (10.9%) of POAG patients with depression was significantly higher (P=0.026) than in the reference subjects (5.2%). Between the POAG patients with and without beta-blocker eye-drops, no significant difference (P=0.93) in the prevalence of depression was noted.

Conclusions: POAG was related to anxiety and depression. No significant relationship between the use of beta-blocker eye-drops and depression was noted.

Publication types

  • Multicenter Study

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Anxiety Disorders / epidemiology*
  • Case-Control Studies
  • Depressive Disorder / epidemiology*
  • Female
  • Glaucoma, Open-Angle / drug therapy
  • Glaucoma, Open-Angle / epidemiology*
  • Humans
  • Intraocular Pressure
  • Japan / epidemiology
  • Male
  • Prevalence
  • Prospective Studies
  • Psychiatric Status Rating Scales
  • Surveys and Questionnaires
  • Visual Acuity

Substances

  • Adrenergic beta-Antagonists